Login to Your Account



Earnings Roundup

Rising Revlimid Demand Helps Celgene's Second-Quarter EPS

By Catherine Shaffer
Staff Writer

Friday, July 27, 2012
Celgene Corp., of Summit, N.J., exceeded analysts' estimates modestly in its second-quarter earnings report, turning in total revenues of $1.367 billion, a 16 percent increase over the second quarter of 2011. Those revenue increases were led by growing sales of multiple myeloma blockbuster Revlimid (lenolidomide).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription